The Department is excited to announce the activation of a trial only available at UCI: “Pembrolizumab combined with radiotherapy for metastatic sarcoma.” Based on Dr. Harris’ research, this original study is a single-arm clinical trial determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma for patients who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curative surgery. For additional details including enrollment information, please click here: https://clinicaltrials.icts.uci.edu/trial/NCT05488366